Johns Hopkins Medicine: Novel Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers
April 07, 2023
April 07, 2023
BALTIMORE, Maryland, April 7 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could becom . . .
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could becom . . .